KineMed, Pfizer partner on biomarkers
KineMed’s platform technology provides a proprietary, rate-based approach for developing novel biomarkers. By utilizing mass spectroscopy and stable isotope labeling of protein turnover, KineMed biomarkers provide rates of change of key proteins involved with therapeutic efficacy and target engagement.
Pfizer has licensed access to the KineMed platform and rights to pursue discovery, development and potential commercialization of kinetic biomarkers in various fields. Both companies will work together on discovery research of novel biomarkers, and Pfizer will be responsible for the development and potential commercialization of any novel biomarkers or companion diagnostics for the Pfizer-selected targets.
KineMed will receive an upfront payment, as well as funding for R&D costs associated with Pfizer-selected targets. In addition, KineMed is eligible to receive development and regulatory milestone payments.
“We believe our kinetic biomarker platform provides real advantages over other approaches to biomarker discovery in de-risking and advancing medicines development, and this collaboration with Pfizer is an important step toward helping us realize the full potential of this technology,” said KineMed President Patrick Doyle.